StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note published on Thursday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Down 4.1 %

NASDAQ IRIX opened at $1.64 on Thursday. The stock has a 50-day moving average of $1.66 and a 200-day moving average of $1.86. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. IRIDEX has a 1-year low of $1.27 and a 1-year high of $3.65. The firm has a market cap of $27.28 million, a PE ratio of -2.45 and a beta of 0.81.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The company had revenue of $11.58 million during the quarter. During the same period in the prior year, the firm earned ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.